Results 191 to 200 of about 11,049 (220)
Some of the next articles are maybe not open access.
Propofol in the treatment of refractory status epilepticus
Intensive Care Medicine, 2006To study prospectively the effects of propofol anesthesia on seizure control, hemodynamics and course of intensive care in patients with refractory status epilepticus.Prospective observational study in the general intensive care unit in a tertiary university hospital.Ten patients with refractory status epilepticus.Patients received propofol anesthesia ...
Ilkka, Parviainen +4 more
openaire +2 more sources
Pentobarbital treatment of refractory status epilepticus
Neurology, 1987We studied nine patients with status epilepticus refractory to standard therapy. In all patients so treated, IV pentobarbital terminated seizure activity. Mortality was high (77%) in those treated, but was attributed to underlying pathology and possibly to duration of status epilepticus.
M C, Rashkin, C, Youngs, P, Penovich
openaire +2 more sources
Treatment strategies for refractory status epilepticus
Current Opinion in Critical Care, 2011Status epilepticus is one of the most common emergencies in neurology, and every third patient does not respond to adequate first-line treatment. Refractory status epilepticus may be associated with increased morbidity and mortality, and new treatment options are urgently required.
openaire +2 more sources
Midazolam in Refractory Status Epilepticus
Annals of Pharmacotherapy, 1996D, Denzel, A H, Burstein
openaire +2 more sources
Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
Epilepsia, 2021+2 more
exaly
Histopathology of new-onset refractory status epilepticus (NORSE) in adults
Seizure: the Journal of the British Epilepsy Association, 2021Sandeep Mittal +2 more
exaly
Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus
Journal of Clinical Medicine, 2021Ayham Alkhachroum +2 more
exaly
Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment
Journal of Neuroimmunology, 2022Hideki Mochizuki +2 more
exaly

